health

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

TL;DR

  • GSK is in talks to acquire Nuvalent for over $9 billion.
  • This would be GSK's largest acquisition in over a decade.
  • The deal could be finalized as early as this week.
  • Nuvalent has two key assets, neladalkib and zidesamtinib, for lung cancer currently under FDA review.
  • The acquisition comes during a period of high activity in biotech dealmaking.
  • The deal would represent a premium of 29% to 43% over Nuvalent's current market capitalization.

Continuer la lecture de l'article original